India has long been known as the “pharmacy of the world” for supplying affordable generic drugs and vaccines. But the country achieved a major milestone in pharmaceutical innovation last year: Nafithromycin (brand name Miqnaf), developed by India’s Wockhardt with support from the Biotechnology Industry Research Assistance Council (BIRAC). This is India’s first novel antibiotic created in-house to combat drug-resistant infections, specifically Community-Acquired Bacterial Pneumonia (CABP).
Antimicrobial resistance (AMR) is a global health emergency, projected to cause up to 10 million deaths annually by 2050. Pneumonia is a leading contributor, with India accounting for 23% of global pneumonia deaths and reporting 4 million CABP cases each year. The lack of new antibiotic classes since the 1980s has worsened the crisis, as pharmaceutical companies have largely abandoned antibiotic R&D due to low profitability and short treatment cycles. Nafithromycin demonstrates how public-private collaboration can overcome these market failures.
Key Features of Nafithromycin
- Clinical superiority: Ten times more effective than azithromycin, with a short three-day treatment regimen that improves patient compliance.
- Broad spectrum: Effective against both typical and atypical pathogens, including resistant strains.
- Safety profile: Few gastrointestinal side effects, minimal drug interactions, and well-tolerated across dosage levels.
- Global significance: First antibiotic of its class in over 30 years, positioning India as a contender in pharmaceutical innovation.
Broader Impact
Developing Nafithromycin took 14 years, reflecting the long timelines and financial challenges of antibiotic innovation. While large pharmaceutical companies have retreated from this space, small and medium firms now drive 80% of new antibiotic discoveries. India’s success highlights the importance of PPPs in addressing AMR and advancing global health resilience.
